Wealth Enhancement Advisory Services
PTGX icon

Wealth Enhancement Advisory Services’s Protagonist Therapeutics PTGX Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$520K Buy
3,958
+301
+8% +$31.4K ﹤0.01% 2652
2026
Q1 		$380K Buy
3,657
+103
+3% +$9.12K ﹤0.01% 2559
2025
Q4 		$292K Buy
3,554
+43
+1% +$3.52K ﹤0.01% 2943
2025
Q3 		$230K Buy
+3,511
New +$200K ﹤0.01% 3005

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Wealth Enhancement Advisory Services's PTGX Position: Q2 2026 in Review

Wealth Enhancement Advisory Services increased its Protagonist Therapeutics (PTGX) stake by 8.2% in Q2 2026, buying an estimated $31.4K and bringing the position to 3,958 shares worth $520K. The position accounts for ﹤0.01% of the portfolio, ranked #2652.

Wealth Enhancement Advisory Services first reported a position in PTGX in Q3 2025 and has held it in 4 quarters since. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Wealth Enhancement Advisory Services held 3,958 shares of Protagonist Therapeutics worth $520K as of Q2 2026.
  • Wealth Enhancement Advisory Services bought 301 Protagonist Therapeutics shares in Q2 2026, an estimated $31.4K.
  • Protagonist Therapeutics made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #2652 holding.
  • Wealth Enhancement Advisory Services first reported a position in Protagonist Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.